Get started
Author

Yiming Cheng

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
2022 · Sagar Lonial, Rakesh Popat, et al. · The Lancet Haematology · 102
Depression Detection on Social Media with Large Language Models
2025 · Xiaochong Lan, Zhiguang Han, et al. · Conference on Empirical Methods in Natural Language Processing: Industry Track (EMNLP) · 42
PDF
Effects of probiotic supplements on the progression of chronic kidney disease: A meta‐analysis
2018 · Sibei Tao, Siying Tao, et al. · Nephrology · 37
How does the brain remove its waste metabolites from within?
2019 · Yiming Cheng, James Haorah · PubMed · 28
Alcohol promotes waste clearance in the CNS via brain vascular reactivity
2019 · Yiming Cheng, Xinglei Liu, et al. · Free Radical Biology and Medicine · 27
Hemorrhage Associated Mechanisms of Neuroinflammation in Experimental Traumatic Brain Injury
2019 · Xiaotang Ma, Yiming Cheng, et al. · Journal of Neuroimmune Pharmacology · 24
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
2022 · Catherine Thieblemont, Javier Munoz, et al. · Blood · 15
Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class–Exposed Relapsed/Refractory Multiple Myeloma
2025 · Fan Wu, Jian Zhou, et al. · Clinical Pharmacokinetics · 11
PDF
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
2025 · Hongxiang Hu, Yan Li, et al. · Clinical Cancer Research · 10
Exploring Transformer Model in Longitudinal Pharmacokinetic/Pharmacodynamic Analyses and Comparing with Alternative Natural Language Processing Models
2024 · Yiming Cheng, Hongxiang Hu, et al. · Journal of Pharmaceutical Sciences · 10
PDF
Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
2021 · Yiming Cheng, Xiaomin Wang, et al. · The Journal of Clinical Pharmacology · 10
Biphasic Effects of Ethanol Exposure on Waste Metabolites Clearance in the CNS
2021 · Yiming Cheng, Xiaotang Ma, et al. · Molecular Neurobiology · 10
Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs
2024 · Yiming Cheng, Shuyu Chu, et al. · Journal of Clinical Oncology · 9
Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma
2022 · Yiming Cheng, Yongjun Xue, et al. · British Journal of Clinical Pharmacology · 8
Renoprotective effects of renin–angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients
2016 · Yiming Cheng, Rongshuang Huang, et al. · Medicine · 8
Integrating Full Bayesian Inference and Student's t‐Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug–Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients
2024 · Yiming Cheng, Shengnan Du, et al. · The Journal of Clinical Pharmacology · 7
A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects
2024 · Yiming Cheng, Xiaomin Wang, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 6
Hemolytic iron regulation in traumatic brain injury and alcohol use
2023 · Agnieszka Agas, Arun Reddy Ravula, et al. · Alcohol · 6
Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a student’s t-based M3 censoring approach for robust handling of outliers and BLQ data
2025 · Yiming Cheng, Hongxiang Hu, et al. · Journal of Pharmaceutical Sciences · 5
Enhancing pharmacometric modeling with full Bayesian inference and Student’s t-Based M3 Censoring: A simulated population PK study on robust handling of outliers and censored data
2025 · Yiming Cheng, Yan Li · Journal of Pharmaceutical Sciences · 5
PDF
P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial
2022 · Niels W.C.J. van de Donk, Marc S. Raab, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
The Association of Enlarged Perivascular Space with Cerebrospinal Fluid GFAP in Early Parkinson’s Disease
2025 · Qiuyue Li, Xueqin Bai, et al. · Academic Radiology · 4
PDF
Population Pharmacokinetics of CC-122
2021 · Yiming Cheng, Jian Chen, et al. · Clinical Pharmacology Advances and Applications · 4
PDF
Association between age-related musculoskeletal diseases and Parkinson disease: a population-based cohort study of UK Biobank
2025 · T. Yang, J. Huang, et al. · Parkinsonism & Related Disorders · 3
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
2023 · Yiming Cheng, Ying Ye, et al. · Clinical Pharmacology Advances and Applications · 3
PDF
Works count: 75
Citation count: 420
H-index: 10
I10-index: 12
Year
Topic
Type